Skip to Main Content

Paper Details

Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Blood
155
2020
ALL, ALLs, CREBBP, FPGS, MSH2, MSH6, NR3C1, NR3C2, NT5C2, PMS2, PRPS1, PRPS2, TP53, WHSC1, acute lymphoblastic leukemia, cancer, drug resistance gene, germline, non, patients, pediatric, persistent clone, relapsed acute lymphoblastic leukemia, resistant clone, subclones, thiopurine
Author NameAffiliation
Xiaotu MaSt. Jude Children's Research Hospital
Xiaotu MaSt. Jude Children's Research Hospital
Yongjin LiSt. Jude Children's Research Hospital
Yongjin LiSt. Jude Children's Research Hospital
Li DongSt. Jude Children's Research Hospital
Li DongSt. Jude Children's Research Hospital
Yu LiuSt. Jude Children's Research Hospital
Yu LiuSt. Jude Children's Research Hospital
Yanling LiuSt. Jude Children's Research Hospital
Yanling LiuSt. Jude Children's Research Hospital
Xin ZhouSt. Jude Children's Research Hospital
Xin ZhouSt. Jude Children's Research Hospital
Edgar SiosonSt. Jude Children's Research Hospital
Edgar SiosonSt. Jude Children's Research Hospital
Michael RuschSt. Jude Children's Research Hospital
Michael RuschSt. Jude Children's Research Hospital
Michael N EdmonsonSt. Jude Children's Research Hospital
Michael N EdmonsonSt. Jude Children's Research Hospital
John EastonSt. Jude Children's Research Hospital
John EastonSt. Jude Children's Research Hospital
Cheng Cheng
Benjamin J RaphaelPrinceton University
Ludmil B AlexandrovUniversity of California
Ludmil B AlexandrovUniversity of California
Ching-Hon PuiSt. Jude Children's Research Hospital
Jinghui ZhangSt. Jude Children's Research Hospital
Jinghui ZhangSt. Jude Children's Research Hospital
  • 1 - 27

Datasets